| Literature DB >> 30634603 |
Chukwuemeka R Nwokocha1, Isheba Warren2, Javier Palacios3, Mario Simirgiotis4, Magdalene Nwokocha5, Sharon Harrison6, Rory Thompson7, Adrian Paredes8, Jorge Bórquez9, Astrid Lavado10, Fredi Cifuentes11.
Abstract
Guinep is traditionally used in the management of cardiovascular ailments. This study aims to evaluate its medicinal constituents and effects in the management of myocardial injury in an experimental isoproterenol (ISO) rat model. Sprague-Dawley rats were randomly assigned to four groups: Group 1 was the control group; Group 2 received M. bijugatus extract (100 mg/Kg; MB) for six weeks; Group 3 was given ISO (85 mg/Kg) i.p. twice during a 24-hour period; and Group 4 was given ISO (85 mg/Kg) i.p. and MB extract (100 mg/Kg) for six weeks. The MB was administered orally by gavage, daily. The blood pressure of conscious animals was measured, while ECG was performed under anesthesia. Blood and serum were collected for biochemical and hematological analysis. The ISO group treated with MB showed a significant decrease (p < 0.001) in (SBP), diastolic (DBP), mean arterial (MAP) and heart rate (HR) compared to the ISO only group. Conversely, MB treated rats that were not induced with ISO displayed a significant decreases (p < 0.001) in SBP, DBP, MAP, and HR. ISO significantly elevated the ST segment (p < 0.001) and shortened the QTc interval (p < 0.05), which were recovered after treatment with 100 mg/Kg of MB. In addition, the results showed a significant decrease (p < 0.001) in the heart to body weight ratio of the ISO group treated with MB compared to the ISO only group. Furthermore, the extract normalized the hematological values depressed by the ISO while significantly elevating the platelet count. UHPLC high-resolution orbitrap mass spectrometry analysis results revealed the presence of several antioxidants like vitamin C and related compounds, phenolic acids, flavonoid, fatty acids (oxylipins), and terpene derivatives. The results of this study indicated that Melicoccus bijugatus did display some cardio-protective effects in relation to myocardial injury.Entities:
Keywords: Melicoccus bijugatus; high-resolution orbitrap mass spectrometry; isoproterenol; myocardial infarction; rat
Mesh:
Substances:
Year: 2019 PMID: 30634603 PMCID: PMC6359499 DOI: 10.3390/molecules24020235
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Effects of Melicoccus bijugatus (MB; 100 mg/Kg) on mean arterial blood pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), and heart rate (HR) of normotensive rats and those with myocardial damage with ISO.
| Normotensive | Myocardial Damage | |||
|---|---|---|---|---|
| Control | MB | ISO | ISO + MB | |
| MAP, mmHg | 101 ± 3 | 69 ± 2 *** | 113 ± 5 | 83 ± 6 *,### |
| SBP, mmHg | 131 ± 3 | 85 ± 2 *** | 133 ± 4 | 106 ± 6 ***,### |
| DBP, mmHg | 87 ± 5 | 60 ± 3 *** | 108 ± 8 * | 72 ± 8 ### |
| PP, mmHg | 44 ± 5 | 27 ± 2 *** | 28 ± 2 ** | 27 ± 3 ** |
| HR, bpm | 246 ± 25 | 146 ± 11 ** | 307 ± 20 | 181 ± 18 ### |
Values are mean ±standard error of the mean of five experiments in mmHg. Statistically significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control; ### p < 0.001 vs. ISO.
Figure 1Electrocardiograms (ECG) showing the bradycardic effects of M. bijugatus extract (MB, 100 mg/Kg) in myocardial injury. Control shows the normal electrocardiograph. ISO (85 mg/Kg) shows an elevated ST segment; ISO + MB shows a restored ST segment.
Figure 2Treatment, with M. bijugatus, of a myocardial injury caused by ISO. The data shows the effects of MB and ISO on ST segment elevation (A) and the duration of the QTc interval of the ECG (B). ISO (85 mg/Kg) significantly elevated the ST segment (p < 0.001) and shortened the QTc interval (p < 0.05), which recovered after treatment with 100 mg/Kg of M. bijugatus. The extract did not, per se, cause any change. * p ˂ 0.05, *** p ˂ 0.001 vs. control; n = 5.
Effect of M. bijugatus on white cell parameters in ISO-induced cardiac injury.
| Control | MB | ISO | ISO + MB | |
|---|---|---|---|---|
| WBC (103/µL) | 9.5 ± 1.2 | 8.6 ± 1.3 | 4.1 ± 1.0 * | 7.1 ± 1.2 |
| LYM (103/µL) | 5.8 ± 0.6 | 5.9 ± 1.0 | 3.0 ± 0.8 | 4.9 ± 0.8 |
| MID (103/µL) | 1.5 ± 0.2 | 1.1 ± 0.2 | 0.62 ± 0.2 * | 1.1 ± 0.1 |
| GRA (103/µL) | 2.4 ± 0.5 | 1.5 ± 0.3 | 0.5 ± 0.1 ** | 1.2 ± 0.3 |
| LYM (%) | 61.4 ± 2.9 | 66.8 ± 2.7 | 73.9 ± 0.9 ** | 69.6 ± 1.1 |
| MID (%) | 14.5 ± 0.6 | 13.9± 1.0 | 14.5 ± 0.8 | 13.2 ± 1.5 |
| GRA (%) | 27.3 ± 0.9 | 19.3 ± 2.4 | 11.6 ± 1.0 *** | 17.3 ± 1.4 * |
WBC—White blood count, LYM—Lymphocyte, MID—Others white cells, GRA—Granulocyte. Values are mean ±standard error of the mean of five experiments in mmHg. Statistically significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control.
Effect of M. bijugatus on red cell and trombocytes parameters in the ISO-induced cardiac injury.
| Control | MB | ISO | ISO + MB | |
|---|---|---|---|---|
| RBC (106/µL) | 6.8 ± 0.2 | 5.9 ± 0.4 | 5.2 ± 0.2 ** | 6.3 ± 0.42 |
| HGB (g/dL) | 14.8 ± 0.3 | 13.6 ± 0.6 | 12.5 ± 0.6 | 14.1 ± 1.0 |
| HCT (%) | 40.0 ± 0.8 | 36.2 ± 1.2 | 32.6 ± 1.5 ** | 34.8 ± 1.4 |
| MCV (fL) | 2.4 ± 0.5 | 1.5 ± 0.3 | 0.5 ± 0.1 ** | 1.2 ± 0.3 |
| MCH (pg) | 21.7 ± 0.2 | 22.2 ± 0.5 | 24 ± 0.6 ** | 22.2 ± 0.4 |
| MCHC (g/dL) | 37.1 ± 0.4 | 37.4 ± 0.6 | 38.6 ± 0.4 | 37.7 ± 0.2 |
| RDW | 15.0 ± 0.3 | 15.7 ± 0.5 | 15.3 ± 1.2 | 16.6 ± 0.9 |
| PLT (103/µL) | 680.3 ± 31.0 | 840.0 ± 21.1 * | 668.8 ± 49.0 | 918.8 ± 42.7 **,## |
| MPV | 6.6 ± 0.2 | 7.7 ± 0.4 | 7.0 ± 0.2 | 7.4 ± 0.5 |
RBC—Red blood count, HGB—Hemoglobin, HCT—Hematocrit, MCV—Mean corpuscular volume, MCH—Mean corpuscular hemoglobin, MCHC—Mean corpuscular hemoglobin concentration, RDW—Red cell distribution width, PLT—Platelets, MPV—Mean platelet volume. Values are mean ±standard error of the mean of five experiments in mmHg. Statistically significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control; ## p < 0.01 vs ISO.
Figure 3Histological analysis of myocardial injury. Histomicrograph of transverse sections of the heart [×200; hematoxylin and eosin stain] taken through the ventricles, just below the atrioventricular valves of control (A), 100 mg/Kg MB alone (B), ISO treatment alone (C), ISO + MB (D). The ISO group showed myocardial infarction in the central region of the left ventricular muscle wall (C). The Control (A) and MB only group (B) displayed no features of myocardial injury. The arrows demonstrated the area of fibrosis.
Figure 4Effects of ISO and treatment with M. bijugatus extract on weight/body weight ratio. Depicts the ISO (85 mg/Kg) induced myocardial damage through an elevation of the heart weight to body weight ratio. This was significantly reduced in the MB (100 mg/Kg) treated groups. ** p ˂0.01 vs. control; ### p ˂ 0.001 vs. ISO, n = 5.
Figure 5UHPLC chromatogram total ion current [total ion current (a), UV at 280 nm (b)] of aqueous extract of M. bijugatus. The details of metabolites are in the Supplementary Material S1.
Identification of metabolites by UHPLC-PDA-OT-MS.
| Peak | Retention Time (min) | UV Max | Tentative Identification | Elemental Composition [M − H]− | Theoretical Mass ( | Measured Mass ( | Accuracy (dppm) | MSn Ions (dppm) |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.72 | 220 | Citric acid | C6H7O7− | 191.01863 | 191.01933 | 3.68 | |
| 2 | 1.82 | 222 | Isocitric acid | C6H7O7− | 191.01863 | 191.01955 | 3.04 | |
| 3 | 1.65 | - | Saccharose | C12H21O11− | 341.10784 | 341.10783 | 2.44 | |
| 4 | 2.55 | - | Glucose | C6H11O6− | 179.05501 | 179.05550 | 2.69 | |
| 5 | 3.37 | 230 | Furoic acid | C5H3O3− | 111.00767 | 111.00787 | 3.25 | |
| 6 | 6.35 | 245 | Salicilic acid glucoside | C13H15O8− | 299.07614 | 299.07712 | 3.25 | 137.02440 |
| 7 | 9.80 | 245–325 | Aflavarin | C24H21O9− | 453.11801 | 453.11703 | −2.1 | |
| 8 | 10.24 | - | Trihydroxyoctadecatrienoic acid | C18H29O5− | 325.20205 | 325.18443 | −54.2 | |
| 9 | 11.98 | 275–339 | Coumaric acid glucoside | C15H17O8− | 325.09179 | 325.09277 | 3.01 | 163.0291, 145.02870, 117.03368 |
| 10 | 12.24 | 275–339 | Coumaric acid galactoside | C15H17O8− | 325.09179 | 325.09271 | 2.82 | 163.0291, 145.02870, 117.03368 |
| 11 | 13.35 | 275–339 | Feruloyl glucoside | C16H19O9− | 355.10346 | 355.10336 | 3.34 | 147.04449, 193.05058 |
| 12 | 15.02 | 254–354 | Isorhamnetin-3- | C22H21O11− | 477.11679 | 477.11670 | −27.12 | 314.04370 |
| 13 | 15.83 | 275–339 | Feruloyl galactoside | C16H19O9− | 355.10346 | 355.10355 | 3.34 | 147.04449, 193.05056 |
| 14 | 21.57 | 236–329 | 3- | C16H17O9− | 353.0878 | 353.0878 | 0.53 | 191.05608 |
| 15 | 21.87 | - | Rishitin | C14H22O2− | 221.15361 | 221.15488 | 5.74 | |
| 16 | 23.54 | 300 | Embelin | C17H26O4− | 293.17474 | 293.17587 | 3.87 | |
| 17 | 25.38 | 235 | Sedanenolide | C12H15O2− | 191.10666 | 191.10741 | 3.92 | |
| 18 | 26.45 | 225 | Valerenic acid | C15H21O2− | 233.15470 | 233.15455 | 3.87 | 149.13301 |
| 19 | 27.78 | 214 | Blumenol C | C13H22O2− | 209.15631 | 209.15430 | 3.30 | |
| 20 | 28.32 | 220 | Hydroxyheptadecatrienoic acid | C17H27O7− | 311.18640 | 311.16876 | −56.6 |